Redeye initiates coverage of Oncopeptides, a commercial-stage biotech company focusing on multiple m...
Cibus' Q1 2024 income from property management (IFPM) was 7% below Infront consensus, adjusted for o...
Solid 7% organic growth in Q1, underlying was even better Another $3m in restructuring costs reveals...
Drop in sales due to tough comps Gross margin negatively impacted by mix effects EBITDA revised down...
Q1e: orders -2%, sales +1% y-o-y, adj. EBITA margin 7.
Gasporox’s results closely align with RRe expectations, showing seven quarters of positive EBITDA dr...
Q1-rapporten – svaga volymer och svårt jämförelsetal Nettoomsättningen sjönk med 32% y/y, varav 27% ...
Finnair’s Q1 earnings were in line with estimates even though top line came in a bit lower than esti...
Redeye comments on the update from the type C FDA meeting.
Lyckegård Group AB (”Lyckegård” eller ”Bolaget”) har renodlat verksamheten mot bevattning och grönyt...
Fine 7% Group organic growth which could have been better No news on CMS reimbursement, Guidance add...
Atria reported Q1 adjusted EBIT of EUR 8.0m, 114% (EUR 4.
Redeye comments on Fantasma Games ahead of its Q1 results (due on 8 May).
Redeye comments on the Q1 report released earlier this morning.
Redeye comments on yesterday’s press release from Xspray that it has successfully scaled up its ASP ...
Redeye states the report aligned with its estimates, and Gasporox has now produced positive EBITDA s...
Q1 sales hurt by lower US sales, but other regions contributed well Fine-tuned sales estimates, but ...
Q1 report due Thursday, 25 April at 07:00 CET '24e-'26e EBITA up 4-5%; 6% CAGR '23-'26e 11-9x EBITA ...
En nedskrivning tyngde resultatet för fjärde kvartalet och under januari lanserade Soltech uppdatera...
Q1e a seasonally small quarter Divests loss-making business, EBITA margin +0.